Focus: Cabaletta Bio is a Philadelphia-based public biotech company developing chimeric auto antibody receptors (CAABs) targeting autoimmune and inflammatory diseases. The company is early-stage, with no approved products and a pipeline focused on systemic lupus erythematosus, myasthenia gravis, pemphigus vulgaris, and other autoimmune indications.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Cabaletta Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cabaletta Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cabaletta Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pemphigus Vulgaris Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - StreetInsider
Pemphigus Vulgaris Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight StreetInsider
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns - Seeking Alpha
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns Seeking Alpha
Cabaletta Bio Slides As Insider Purchases Lose Another US$60k - Simply Wall St
Cabaletta Bio Slides As Insider Purchases Lose Another US$60k Simply Wall St
Cabaletta Bio (Nasdaq:CABA) - Stock Analysis - Simply Wall Street
Cabaletta Bio (Nasdaq:CABA) - Stock Analysis Simply Wall Street
Cellares pens 2nd automation test with Asia-based cell therapy partner in 2 weeks - Fierce Pharma
Cellares pens 2nd automation test with Asia-based cell therapy partner in 2 weeks Fierce Pharma
H.C. Wainwright Keeps Their Buy Rating on Cabaletta Bio (CABA) - The Globe and Mail
H.C. Wainwright Keeps Their Buy Rating on Cabaletta Bio (CABA) The Globe and Mail
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo